|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Stakeholder Opinions: Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders. With a forecast incidence of 36,769 across the seven major markets in 2007, they are one of the most common hematological malignancies. Currently, the only
Stakeholder Opinions: Hepatocellular Carcinoma
The close association with hepatitis means that hepatocellular carcinoma (HCC) is common in developing countries where hepatitis B and C infections are endemic. However, the increasing prevalence of hepatitis in the West means that incidence of HCC in
Stakeholder Opinions: Female Sexual Dysfunction
Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the cl
Stakeholder Opinions: Esophageal Cancer
Globally, esophageal cancer is the ninth most common tumor type and seventh leading cause of cancer-related death, however, its incidence fluctuates widely depending on geographical area. While relatively uncommon in Western countries, 50% of patients
Non-hormonal Treatments for Menopausal Symptoms
The treatment of menopausal symptoms is a common clinical challenge, with vasomotor symptoms affecting an estimated 75% of women aged over 50 years. Hormone replacement therapy (HRT) has formed the mainstay of treatment for almost 60 years and is highl
Stakeholder Opinions: Primary Brain Cancer
Incidence of primary brain cancer across the seven major markets in 2007 is estimated to be 47,000. Over half of these cases will be glioblastoma multiforme, for which survival prospects are dismal. The median survival for this group of patients is 1.2
Stakeholder Opinions: Alpha 1 Antitrypsin Deficiency
Investigation of the state of alpha-1 antitrypsin deficiency market, discussion of the regional variability of predisposing genotypes, disease description, pipeline details and factors hindering the development of new treatments.
Stakeholder Opinions: Bone Metastases
Key issues in bone metastases, including mechanisms of normal and altered bone metabolism, epidemiology data, current treatment options, unmet needs, analysis of pipeline drugs in direct development for bone metastases and key stakeholder opinions.
Stakeholder Opinions: Multiple Myeloma
The incidence of multiple myeloma is forecast to total 40,885 cases across the seven major pharmaceutical markets in 2007. Current drug therapy is planned around stem cell transplantation. The recent approval of three new agentsThalomid (thalidomide; C
Stakeholder Opinions: Sepsis
Key issues surrounding product development for sepsis, severe sepsis and septic shock. Analysis of the major clinical and commercial defining the four key areas of optimised individual treatment: predisposition, infection, response and organ failure.
Stakeholder Opinion: Atopic Dermatitis
Atopic dermatitis is a skin disorder characterized by intense itch, dry skin and redness. Often considered a benign disease, it actually impacts very negatively on quality of life, sometimes more than psoriasis and diabetes. Through opinion leader inte
Stakeholder Opinions: Percutaneous Coronary Intervention
While drug eluting stents have been successful in reducing the rate of restenosis following percutaneous coronary intervention, there have been safety scares over a new problem: "in-stent thrombosis". Opinion leaders are divided over the grav
Stakeholder Opinions: Non-Hodgkins Lymphoma
Non-Hodgkin’s lymphoma (NHL) is the most common hematological malignancy and is comprised of around 30 different disease subtypes. Each of these present with a distinct set histological, genetic and clinical characteristics. Treatment options in
Stakeholder Opinions: Fibromyalgia
Mainly affecting women, fibromyalgia syndrome affects six million people in the US alone. This relatively common yet poorly understood syndrome is characterized by widespread muscle pain and fatigue and remains substantially underserved by the medical
Stakeholder Opinions: Biologics in Infectious Diseases
Explores key issues in the development of biologics for infectious diseases. It identifies promising targets, highlights development difficulties and gives an overview of antibacterial, antiviral and antifungal pipeline projects.
Stakeholder Opinions: Hepatitis C
Research and Development activity in the Hepatitis C arena continue to be high. The market still holds many areas of unmet medical needs: while existing therapies provide good efficacy for about half of the patient population, side effects and limited
Stakeholder Opinions: Portable Inhaler Devices
An overview ofthe market for portable inhalers, looking at market shares,usefulness as tools for franchise protection and -expansion. Patient- and physician preferences are being analyzed as well as suitablility of molecules and inhaler types.
Stakeholder Opinions: Renal Cell Carcinoma - Novel Targeted...
A meager 20% of metastatic RCC tumors respond to standard cytokine therapy, thus rendering 80% of advanced RCC patients without any effective treatment. Further, with up to 50% of stage one to three patients relapsing following nephrectomy and an incre
Stakeholder Opinions: Sexually Transmitted Infections
The global incidence of STIs is estimated at several hundreds of millions cases per year, and due to the asymptomatic nature of most infections, underreporting is likely to mask the real incidence. Most STIs can lead to severe sequelae, including infer
Stakeholder Opinions: Chronic Leukemias - Curative Intent
Recognizing that prolonging disease-free survival in chronic leukemia relies on the eradication of minimal residual disease has raised the bar for developers of novel pharmacotherapy. In meeting the more demanding success criteria and targeting innovat
Stakeholder Opinions: Minimally Invasive Spinal Surgery...
As in other areas of surgery, surgeons are looking to reduce the invasive nature of spinal surgery, in an attempt to improve patient outcomes. The potential benefits of minimally invasive spinal surgery such as microdiscectomy and mini spinal fusion in
Stakeholder Opinions: Brain Metastases
The incidence of brain metastasis is escalating concurrent with improvements in systemic therapy increasing patient survival. There is no approved pharmacotherapy for these patients and current therapy is palliative. Median survival is four months. Thu
Stakeholder Opinions: Migraine - Lots of Experience...
Headache is the most common complaint seen in family practice in the US, yet medical training gives little time to its diagnosis and treatment. Enabling improved diagnosis and an understanding of suitable treatment pathways for migraine will allow phar
|